Question 1

What is VGA039?

Accepted Answer

VGA039 is a Other.

Question 2

How often does VGA039 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was VGA039 first tracked by Ergen?

Accepted Answer

First tracked on Jun 08, 2026.

Question 4

When was VGA039 last mentioned in news?

Accepted Answer

Last active on Jun 18, 2026.

Question 5

What is VGA039's current news sentiment?

Accepted Answer

Aggregate sentiment score: 75 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is VGA039 in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving VGA039?

Accepted Answer

Incyte acquires Vega Therapeutics for VGA039 (Jun 08, 2026, 6 articles).

Question 8

How did the "Incyte acquires Vega Therapeutics for VGA039" event impact VGA039?

Accepted Answer

VGA039 is a novel investigational monoclonal antibody in Phase 3 development for von Willebrand disease, and its acquisition by Incyte is the central focus of this event, promising a new treatment option for patients.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.